<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04333173</url>
  </required_header>
  <id_info>
    <org_study_id>101010</org_study_id>
    <nct_id>NCT04333173</nct_id>
  </id_info>
  <brief_title>Endovascular Therapy for Erectile Dysfunction</brief_title>
  <acronym>RE-ACTION</acronym>
  <official_title>ENDOVASCULAR THERAPY REGISTRY FOR ERECTILE DYSFUNCTION</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica San Gaudenzio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica San Gaudenzio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brief Summary: Background and pathophysiology Erectile dysfunction is a serious disease with
      a significant impact on the quality of life. Male erection is a complex mechanism that
      involves neuro-vascular tissue responses with several phases including arterial dilatation,
      smooth muscle cells relaxation and ultimately veno-occlusive activation. Vasculogenic
      erectile dysfunction can be divided in arteriogenic (when there is insufficiency of arterial
      component of erection due to atherosclerotic plaque encroachment of the penile arteries) or
      venogenic (where there is insufficiency of the venous component of erection for venous
      endoleak) Standard treatment Erectile dysfunction is commonly treated by oral
      phosphodiesterase-5-inhbitor (PDE5i) administration. However, up to 50% of men have a
      suboptimal response to PDE5-i therapy with the need of additional therapies. New treatment
      Only recently several studies have been published on percutaneous treatment of ED using POBA,
      Drug eluting balloons (both paclitaxel and sirolimus, PEB and SES) and drug eluting stents
      (DES).

      Aim of the study The study was aimed at evaluating both arteriogenic and venogenic
      endovascular treatments in patients affected by erectile dysfunction in an Italian patient
      cohort.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description: The objective of this study is to evaluate of the safety and
      feasibility of endovascular therapies in segmental atherosclerotic lesions of the internal
      pudendal arteries among men with erectile dysfunction (ED) and no-response to
      phosphodiesterase-5 inhibitors for at least 6 months either at increasing dosage or with
      different drugs routinely utilized in this setting) before enrollment. All patients will be
      screened by IIEF-5 questionnaire (IEF-5 Score &lt; 15 points); Penile Dynamic Doppler ultrasound
      with intracavernous injection of Caverject (cut-off for Inflow insufficiency: PSV &lt;25 cm s−1,
      EDV &lt;5 cm s−1, RI &gt; 0.8; cut-off for Venous leakage: PSV &gt; 25 cm s−1, EDV &gt; 5 cm s−1, RI &lt;
      0.8; cut-off for mixed pathology: PSV &lt; 25 cm s−1, EDV &gt; 5 cm s−1, RI &lt; 0.8); and/or positive
      angio-CT scan for stenosis of the penile arteries of venous insufficiency. All patients will
      be treated either by POBA+PES/SES or in case of suboptimal result (angiographic residual
      stenosis &gt; 30%) with DES implantation. All patients will be discharged with dual antiplatelet
      therapy for 3 months and with Cialis 5 mg daily for 30 days. Patients will be followed at 1
      mos with IIEF questionnaire, 3 months with IIE-5 questionnaire, 8 months with IIEF
      questionnaire and Dynamic Doppler ultrasound evaluation, and 12 months with IIEF-5
      questionnaire and Dynamic Doppler ultrasound evaluation. Primary endpoints will be the delta
      of IEF-5 score between basal and 8 months FU (&gt;5 points). Delta PSV (&gt;8 points of cm/sec at
      the Dynamic Doppler evaluation) between basal and 8 mos follow-up. 1. Secondary endpoints
      will be a) Incidence of MAE (Death, MI, Stroke), 2) Binary restenosis and late loss in
      patients who will repeat control angiography if clinically indicated for ED recurrence
      (clinically evaluated by either needs to reintroduce/increase PDEF5i dosage on-demand, delta
      IEF-5 &lt;5 compared to 1 mos FU after 6 mos FU) or in patients with bilateral disease with
      scheduled procedure after 6 mos FU from the index procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>IEF-5 SCORE VARIATION AFTER ENDOVASCULAR</measure>
    <time_frame>6 months</time_frame>
    <description>INTERNATIONAL INDEX OF ERECTILE FUNCTION</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSV VARIATION AFTER ENDOVASCULAR TREATMENT</measure>
    <time_frame>6 month</time_frame>
    <description>PUDENDAL DOPPLER PEAK SYSTOLIC VELOCITY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADVERSE EVENTS</measure>
    <time_frame>6-12 months</time_frame>
    <description>Procedural complications; cardiovascular events during follow-up</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Active endovascular treatment</arm_group_label>
    <description>Patients with erectile dysfunction (ED) and no-response to phosphodiesterase-5 inhibitors for at least 6 months before enrollment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endovascular procedure</intervention_name>
    <description>Endovascular therapies for erectile dysfunction</description>
    <arm_group_label>Active endovascular treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with erectile dysfunction (ED) and no-response to phosphodiesterase-5 inhibitors
        for at least 6 months before enrollment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years old

          -  Be able to understand and sign a witnessed informed consent for the procedure

          -  Eligibility for percutaneous peripheral intervention

          -  Baseline IIEF-5 score evaluation &lt; 15

          -  PSV &lt; 25 cm/sec

          -  Stable hemodynamic conditions

          -  Normal ejection fraction

          -  Being refractory to oral PDE5-I for at least 6 months before enrollement

          -  Treatable angiographic lesions of the pudendal arteries

        Exclusion Criteria:

          -  Heart failure

          -  Hemodynamic instability

          -  Basal IIEF-5 and doppler examination

          -  Blood count not within normal ranges

          -  No history of bleeding or coagulopathy

          -  No other serious medical illness

          -  Other investigational drug or device study

          -  Pudendal artery &lt; 1.5 mm and lesion lenght greater than 80 mm by visual estimation

          -  Pudendal restenosis from previous intervention
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Centro Cuore</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Sangiorgi G, Colantonio R, Antonini G, Savino A, Sperandio M. [Percutaneous intervention therapy for vascular erectile dysfunction]. G Ital Cardiol (Rome). 2016 Oct;17(10 Suppl 1):12S-21. doi: 10.1714/2372.25474. Review. Italian.</citation>
    <PMID>27729664</PMID>
  </reference>
  <reference>
    <citation>Doppalapudi SK, Wajswol E, Shukla PA, Kolber MK, Singh MK, Kumar A, Fischman A, Rastinehad AR. Endovascular Therapy for Vasculogenic Erectile Dysfunction: A Systematic Review and Meta-Analysis of Arterial and Venous Therapies. J Vasc Interv Radiol. 2019 Aug;30(8):1251-1258.e2. doi: 10.1016/j.jvir.2019.01.024. Epub 2019 May 17.</citation>
    <PMID>31104902</PMID>
  </reference>
  <reference>
    <citation>Diehm N, Marggi S, Ueki Y, Schumacher D, Keo HH, Regli C, Do DD, Moeltgen T, Grimsehl P, Wyler S, Schoenhofen H, Räber L, Schumacher M. Endovascular Therapy for Erectile Dysfunction-Who Benefits Most? Insights From a Single-Center Experience. J Endovasc Ther. 2019 Apr;26(2):181-190. doi: 10.1177/1526602819829903. Epub 2019 Feb 11.</citation>
    <PMID>30741067</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinica San Gaudenzio</investigator_affiliation>
    <investigator_full_name>Giuseppe Sangiorgi</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>ED</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

